Sandbox pud: Difference between revisions

Jump to navigation Jump to search
Line 130: Line 130:
===Second-line therapies===
===Second-line therapies===
{{rx|Triple therapy}}
{{rx|Triple therapy}}
* [[Proton pump inhibitor]] (standard dose twice daily) for 7–14 days {{and}}
* '''[[Proton pump inhibitor]]''' (standard dose twice daily) for 7–14 days {{and}}
* [[Amoxicillin]] (1 g twice daily) for 7–14 days {{and}}
* '''[[Amoxicillin]]''' (1 g twice daily) for 7–14 days {{and}}
* [[Metronidazole]] (250 mg four times daily) for 7–14 days
* '''[[Metronidazole]]''' (250 mg four times daily) for 7–14 days
</li>
</li>
{{rx|Levofloxacin triple therapy}}
{{rx|Levofloxacin triple therapy}}
* [[Proton pump inhibitor]] (standard dose twice daily) for 10 days {{and}}
* '''[[Proton pump inhibitor]]''' (standard dose twice daily) for 10 days {{and}}
* [[Amoxicillin]] (1 g twice daily) for 10 days {{and}}
* '''[[Amoxicillin]]''' (1 g twice daily) for 10 days {{and}}
* [[Levofloxacin]] (500 mg twice daily) for 10 days
* '''[[Levofloxacin]]''' (500 mg twice daily) for 10 days
</li>
</li>
{{rx|Rifabutin triple therapy}}
{{rx|Rifabutin triple therapy}}
* [[Proton pump inhibitor]] (standard dose twice daily) for 10 days {{and}}
* '''[[Proton pump inhibitor]]''' (standard dose twice daily) for 10 days {{and}}
* [[Amoxicillin]] (1 g twice daily) for 10 days {{and}}
* '''[[Amoxicillin]]''' (1 g twice daily) for 10 days {{and}}
* [[Rifabutin]] (150–300 mg/day) for 10 days
* '''[[Rifabutin]]''' (150–300 mg/day) for 10 days
</li>
</li>



Revision as of 22:44, 7 May 2015

Peptic ulcer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Peptic Ulcer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Upper GI Endoscopy

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic management
Surgical management

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

2017 ACG Guidelines for Peptic Ulcer Disease

Guidelines for the Indications to Test for, and to Treat, H. pylori Infection

Guidelines for First line Treatment Strategies of Peptic Ulcer Disease for Providers in North America

Guidlines for factors that predict the successful eradication when treating H. pylori infection

Guidelines to document H. pylori antimicrobial resistance in the North America

Guidelines for evaluation and testing of H. pylori antibiotic resistance

Guidelines for when to test for treatment success after H. pylori eradication therapy

Guidelines for penicillin allergy in patients with H. pylori infection

Guidelines for the salvage therapy

Sandbox pud On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox pud

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox pud

CDC on Sandbox pud

Sandbox pud in the news

Blogs on Sandbox pud

to Hospitals Treating Peptic ulcer

Risk calculators and risk factors for Sandbox pud

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Antimicrobial agent is indicated for patients with gastric or duodenal peptic ulceration who are colonized with Helicobacter pylori and patients with MALT lymphoma. Eradication therapy should also be considered for patients with immune thrombocytopenic purpura who are H. pylori positive or patients who have undergone resection for early-stage gastric cancer. The use of antibiotics is discouraged in asymptomatic carriers.

Medical Therapy

  • Treatment of H. pylori usually leads to clearing of infection, relief of symptoms and eventual healing of ulcers. Recurrence of infection can occur and retreatment may be required, if necessary with other antibiotics. Since the widespread use of PPI's in the 1990s, surgical procedures (like "highly selective vagotomy") for uncomplicated peptic ulcers became obsolete.


Principles of Eradication Therapy for Helicobacter pylori infection

The following table contains the indications for diagnosis and treatment of Helicobacter pylori infection[1]

Indications for diagnosis and treatment of Helicobacter pylori infection
Active peptic ulcer disease
Confirmed history of peptic ulcer disease not previously treated for H. pylori
Gastric MALT lymphoma
After endoscopic resection of early gastric cancer
  • Low clarithromycin resistance areas (<15%):[2]
    • In areas of low resistance the PPI-clarithromycin-containing triple therapy is recommended as the first-line treatment as well as bismuth-containing quadruple therapy.
    • In areas of low resistance after failure of a PPI-clarithromycin-containing treatment, either a bismuth-containing quadruple therapy or levofloxacin-containing triple therapy is recommended.
  • High clarithromycin resistance areas (≥15%):[2]
    • In areas of high resistance, bismuth-containing quadruple therapy is recommended as the first-line treatment.
    • In areas of high resistance after failure of bismuth containing quadruple therapy, Levofloxacin containing triple therapy is recommended.
  • If the second-line treatment fails, the antibiotic therapy should guided by antimicrobial susceptibility testing.[2]
  • FDA approved first line regimens duration:[3]
    • Triple therapy: 7 days (10 days if rabeprazole is used).
    • Quadruple therapy: 4 weeks.
  • Patients who have had a previous H. pylori associated ulcer or gastric MALT lymphoma or who have had surgical resection for early gastric cancer, confirmation tests for eradication of H. pylori infection should be done.[4]
  • The best nonendoscopic test to confirm eradication of H. pylori infection is the urea breathing test.[3]
  • Testing to prove H. pylori eradication is most accurate if performed 4 weeks after the completion of the therapy.[4]
Countries with a reported prevalence <15% of H. pylori resistance to clarithromycin[5][6][7][8]
Europe North America South America Middle East Far East
  • Belgium (3%)
  • Croatia (8.2%)
  • Denmark (11%)
  • Finland (2%)
  • Germany (2.2–4%)
  • Italy (North) (1.8%)
  • Ireland (8.8%)
  • Netherlands (1.7%)
  • Sweden (2.9%)
  • UK (8.3–12.7%)
  • Canada (12%)
  • USA (10.6–12.2%)
  • Brazil (9.8%)
  • Israel (8.2%)
  • Saudi Arabia (4%)
  • Bangladesh (10%)
  • Hong Kong (4.5%)
  • Korea (14%)
  • Malaysia (2.1%
  • New Zealand (11%)

There is a reported prevalence of 15% in the Northeast of the US.

Countries with a reported prevalence ≥15% of H. pylori resistance to clarithromycin[5][6][7][8]
Europe North America Middle East Far East
  • Bulgaria (18.4%)
  • France (20%)
  • Italy (central) (23.4%)
  • Portugal (22%)
  • Spain (49.2%)
  • Turkey (48.2%)
  • Mexico (25%)
  • Iran (17%)
  • China (18%)
  • India (33%)
  • Japan (27.7%)
  • Taiwan (13.5%)

Eradication Therapy for Helicobacter pylori Infection

Regimens for initial treatment

  • Second-line therapies

  • Contraindicated Medications

    Bleeding peptic ulcer is considered an absolute contraindication to the use of the following medications:

    Guidelines and Resources

    • American College of Gastroenterology (ACG) – Guidelines for the management of dyspepsia.[9]
    • American Society for Gastrointestinal Endoscopy (ASGE) – The role of endoscopy in dyspepsia.[10]
    • American Society for Gastrointestinal Endoscopy (ASGE) – The role of endoscopy in gastroduodenal obstruction and gastroparesis.[11]
    • American College of Cardiology Foundation/American College of Gastroenterology/American Heart Association (ACCF/ACG/AHA) – Reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.[12]

    References

    1. Koperna T, Schulz F (1996). "Prognosis and treatment of peritonitis. Do we need new scoring systems?". Arch Surg. 131 (2): 180–6. PMID 8611076.
    2. 2.0 2.1 2.2 Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F; et al. (2012). "Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report". Gut. 61 (5): 646–64. doi:10.1136/gutjnl-2012-302084. PMID 22491499.
    3. 3.0 3.1 Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology (2007). "American College of Gastroenterology guideline on the management of Helicobacter pylori infection". Am J Gastroenterol. 102 (8): 1808–25. doi:10.1111/j.1572-0241.2007.01393.x. PMID 17608775.
    4. 4.0 4.1 McColl KE (2010). "Clinical practice. Helicobacter pylori infection". N Engl J Med. 362 (17): 1597–604. doi:10.1056/NEJMcp1001110. PMID 20427808.
    5. 5.0 5.1 Mégraud F (2004). "H pylori antibiotic resistance: prevalence, importance, and advances in testing". Gut. 53 (9): 1374–84. doi:10.1136/gut.2003.022111. PMC 1774187. PMID 15306603.
    6. 6.0 6.1 Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C; et al. (2004). "Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States". Emerg Infect Dis. 10 (6): 1088–94. doi:10.3201/eid1006.030744. PMC 3323181. PMID 15207062.
    7. 7.0 7.1 De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C; et al. (2010). "Worldwide H. pylori antibiotic resistance: a systematic review". J Gastrointestin Liver Dis. 19 (4): 409–14. PMID 21188333.
    8. 8.0 8.1 Boyanova L, Mitov I (2010). "Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents". Expert Rev Anti Infect Ther. 8 (1): 59–70. doi:10.1586/eri.09.113. PMID 20014902.
    9. Talley, Nicholas J.; Vakil, Nimish; Practice Parameters Committee of the American College of Gastroenterology (2005-10). "Guidelines for the management of dyspepsia". The American Journal of Gastroenterology. 100 (10): 2324–2337. doi:10.1111/j.1572-0241.2005.00225.x. ISSN 0002-9270. PMID 16181387. Check date values in: |date= (help)
    10. Ikenberry, Steven O.; Harrison, M. Edwyn; Lichtenstein, David; Dominitz, Jason A.; Anderson, Michelle A.; Jagannath, Sanjay B.; Banerjee, Subhas; Cash, Brooks D.; Fanelli, Robert D.; Gan, Seng-Ian; Shen, Bo; Van Guilder, Trina; Lee, Kenneth K.; Baron, Todd H.; ASGE STANDARDS OF PRACTICE COMMITTEE (2007-12). "The role of endoscopy in dyspepsia". Gastrointestinal Endoscopy. 66 (6): 1071–1075. doi:10.1016/j.gie.2007.07.007. ISSN 0016-5107. PMID 18028927. Check date values in: |date= (help)
    11. ASGE Standards of Practice Committee; Fukami, Norio; Anderson, Michelle A.; Khan, Khalid; Harrison, M. Edwyn; Appalaneni, Vasudhara; Ben-Menachem, Tamir; Decker, G. Anton; Fanelli, Robert D.; Fisher, Laurel; Ikenberry, Steven O.; Jain, Rajeev; Jue, Terry L.; Krinsky, Mary Lee; Maple, John T.; Sharaf, Ravi N.; Dominitz, Jason A. (2011-07). "The role of endoscopy in gastroduodenal obstruction and gastroparesis". Gastrointestinal Endoscopy. 74 (1): 13–21. doi:10.1016/j.gie.2010.12.003. ISSN 1097-6779. PMID 21704805. Check date values in: |date= (help)
    12. Bhatt, Deepak L.; Scheiman, James; Abraham, Neena S.; Antman, Elliott M.; Chan, Francis K. L.; Furberg, Curt D.; Johnson, David A.; Mahaffey, Kenneth W.; Quigley, Eamonn M.; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (2008-10-28). "ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents". Circulation. 118 (18): 1894–1909. doi:10.1161/CIRCULATIONAHA.108.191087. ISSN 1524-4539. PMID 18836135.